AAAAAA
Results: 26-50/74
Authors:
ZIV I
SHIRVAN A
BARZILAI A
DJALDETTI R
MELAMED E
Citation: I. Ziv et al., NEURONAL APOPTOSIS TRIGGERED BY DOPAMINE IS ASSOCIATED WITH INDUCTIONOF THE COLLAPSIN SYSTEM, Neurology, 48(3), 1997, pp. 5121-5121
Authors:
SHIRVAN A
ZIV I
MACHLIN T
ZILKHAFALB R
MELAMED E
BARZILAI A
Citation: A. Shirvan et al., 2 WAVES OF CYCLIN-B AND PROLIFERATING CELL NUCLEAR ANTIGEN EXPRESSIONDURING DOPAMINE-TRIGGERED NEURONAL APOPTOSIS, Journal of neurochemistry, 69(2), 1997, pp. 539-549
Authors:
DJALDETTI R
ACHIRON A
ZIV I
DJALDETTI M
MELAMED E
FISHMAN P
Citation: R. Djaldetti et al., IL-3-LA PRODUCTION BY MONONUCLEAR-CELLS OF PATIENTS WITH MULTIPLE-SCLEROSIS - EFFECT OF TREATMENT WITH INTRAVENOUS IMMUNOGLOBULINS (VOL 24,PG 765, 1995), Immunological investigations, 25(4), 1996, pp. 385-386
Authors:
DJALDETTI R
MELAMED E
Citation: R. Djaldetti et E. Melamed, LEVODOPA ETHYLESTER - A NOVEL RESCUE THERAPY FOR RESPONSE FLUCTUATIONS IN PARKINSONS-DISEASE, Annals of neurology, 39(3), 1996, pp. 400-404
Authors:
DJALDETTI R
ATLAS D
MELAMED E
Citation: R. Djaldetti et al., EFFECT OF SUBCUTANEOUS ADMINISTRATION OF LEVODOPA ETHYL-ESTER, A SOLUBLE PRODRUG OF LEVODOPA, ON DOPAMINE METABOLISM IN RODENT STRIATUM - IMPLICATION FOR TREATMENT OF PARKINSONS-DISEASE, Clinical neuropharmacology, 19(1), 1996, pp. 65-71
Authors:
DJALDETTI R
BARON J
ZIV I
MELAMED E
Citation: R. Djaldetti et al., GASTRIC-EMPTYING IN PARKINSONS-DISEASE - PATIENTS WITH AND WITHOUT RESPONSE FLUCTUATIONS, Neurology, 46(4), 1996, pp. 1051-1054
Authors:
DJALDETTI R
ZIV I
ACHIRON A
MELAMED E
Citation: R. Djaldetti et al., FATIGUE IN MULTIPLE-SCLEROSIS COMPARED WITH CHRONIC FATIGUE SYNDROME - A QUANTITATIVE ASSESSMENT, Neurology, 46(3), 1996, pp. 632-635
Authors:
ZIV I
SHIRVAN A
DJALDETTI R
MICHLIN T
BARZILAI A
MELAMED E
Citation: I. Ziv et al., NEURONAL APOPTOSIS INDUCED BY DOPAMINE IS ASSOCIATED WITH CELL CYCLE-RELATED EVENTS - CLUES FOR NIGRAL DEGENERATION IN PARKINSONS-DISEASE, Neurology, 46(2), 1996, pp. 20001-20001
IMPAIRED ABSORPTION OF ORAL LEVODOPA - A MAJOR CAUSE FOR RESPONSE FLUCTUATIONS IN PARKINSONS-DISEASE
Authors:
DJALDETTI R
ZIV I
MELAMED E
Citation: R. Djaldetti et al., IMPAIRED ABSORPTION OF ORAL LEVODOPA - A MAJOR CAUSE FOR RESPONSE FLUCTUATIONS IN PARKINSONS-DISEASE, Israel journal of medical sciences, 32(12), 1996, pp. 1224-1227
Authors:
OFFEN D
ZIV I
STERNIN H
MELAMED E
HOCHMAN A
Citation: D. Offen et al., PREVENTION OF DOPAMINE-INDUCED CELL-DEATH BY THIOL ANTIOXIDANTS - POSSIBLE IMPLICATIONS FOR TREATMENT OF PARKINSONS-DISEASE, Experimental neurology, 141(1), 1996, pp. 32-39
Authors:
DJALDETTI R
MELAMED E
Citation: R. Djaldetti et E. Melamed, POSTRAUMATIC-DELAYED CEREBELLAR SYNDROME, Archives of neurology, 53(12), 1996, pp. 1214-1214
Authors:
YAMASHITA M
ACHIRON A
MIURA T
TAKEHISA J
IDO E
IGARASHI T
IBUKI K
OSAME M
SONODA S
MELAMED E
HAYAMI M
SHOHAT B
Citation: M. Yamashita et al., HTLV-I FROM IRANIAN-MASHHADI JEWS IN ISRAEL IS PHYLOGENETICALLY RELATED TO THAT OF JAPAN, INDIA, AND SOUTH-AMERICA RATHER THAN TO THAT OF AFRICA AND MELANESIA, Virus genes, 10(1), 1995, pp. 85-90
Authors:
DJALDETTI R
KOREN M
ZIV I
ACHIRON A
MELAMED E
Citation: R. Djaldetti et al., EFFECT OF CISAPRIDE ON RESPONSE FLUCTUATIONS IN PARKINSONS-DISEASE, Movement disorders, 10(1), 1995, pp. 81-84
Authors:
DJALDETTI R
ACHIRON A
ZIV I
DJALDETTI M
MELAMED E
FISHMAN P
Citation: R. Djaldetti et al., IL-3-LA PRODUCTION BY MONONUCLEAR-CELLS OF PATIENTS WITH MULTIPLE-SCLEROSIS - EFFECT OF TREATMENT WITH INTRAVENOUS IMMUNOGLOBULINS, Immunological investigations, 24(5), 1995, pp. 765-773
Authors:
YOUDIM MBH
MELAMED E
RECHES A
TATTON W
COMMISSIONG J
LAVY R
FINBERG JPM
Citation: Mbh. Youdim et al., NEUROPROTECTIVE AND NEURORESCUE ACTIVITIES OF RASAGILINE (TVP 1012,N-PROPARGYL-1 [R]-AMINO-INDAN), Annals of neurology, 38(2), 1995, pp. 317-317
Authors:
OFFEN D
ZIV I
STEIN R
HOCHMAN A
SHIRVAN A
PANET H
GORDIN S
BARZILAI A
MELAMED E
Citation: D. Offen et al., CELLULAR PROTECTIVE EFFECT OF BCL-2 AGAINST DOPAMINE-INDUCED APOPTOSIS - AN ASSOCIATION WITH ANTIOXIDANT PATHWAYS, Annals of neurology, 38(2), 1995, pp. 328-328
Authors:
DJALDETTI R
ATLAS D
MELAMED E
Citation: R. Djaldetti et al., LEVODOPA ETHYLESTER - A NOVEL THERAPEUTIC STRATEGY FOR TREATMENT OF RESPONSE FLUCTUATIONS IN PATIENTS WITH PARKINSONS-DISEASE, Annals of neurology, 38(2), 1995, pp. 330-330
Authors:
MELAMED E
Citation: E. Melamed, DOES TREATMENT WITH DOPAMINE AGONISTS AFFECT UTILIZATION OF EXOGENOUSLEVODOPA IN THE PARKINSONIAN STRIATUM, Journal of neural transmission. Supplementum, (45), 1995, pp. 57-60
Authors:
OFFEN D
ZIV I
GORODIN S
BARZILAI A
MALIK Z
MELAMED E
Citation: D. Offen et al., DOPAMINE-INDUCED PROGRAMMED CELL-DEATH IN MOUSE THYMOCYTES, Biochimica et biophysica acta. Molecular cell research, 1268(2), 1995, pp. 171-177
Authors:
NERURKAR VR
ACHIRON A
SONG KJ
MELLAND RR
PINHASHAMIEL O
MELAMED E
SHOHAT B
YANAGIHARA R
Citation: Vr. Nerurkar et al., HUMAN T-CELL LYMPHOTROPIC VIRUS TYPE-I IN IRANIAN-BORN MASHHADI JEWS - GENETIC AND PHYLOGENETIC EVIDENCE FOR COMMON SOURCE OF INFECTION, Journal of medical virology, 45(4), 1995, pp. 361-366
Authors:
ZOLDAN J
FRIEDBERG C
LIVNEH M
MELAMED E
Citation: J. Zoldan et al., PSYCHOSIS IN ADVANCED PARKINSONS-DISEASE - TREATMENT WITH ONDANSETRON, A 5-HT3 RECEPTOR ANTAGONIST, Neurology, 45(7), 1995, pp. 1305-1308
Authors:
ZOLDAN J
FRIEDBERG G
WEIZMAN A
MELAMED E
Citation: J. Zoldan et al., PSYCHOSIS IN LEVODOPA-TREATED PARKINSONIAN-PATIENTS - CLINICAL-FEATURES AND RESPONSE TO ONDANSETRON, A SELECTIVE 5-HT3 ANTAGONIST, Neurology, 45(4), 1995, pp. 167-167
Authors:
GOLDBERGSTERN H
NAVON R
SEIFRIED B
SADEH M
MEER J
GABAY U
MELAMED E
GADOTH N
Citation: H. Goldbergstern et al., CHARCOT-MARIE-TOOTH (CMT) DISEASE IN ISRAEL - CLINICAL, EPIDEMIOLOGIC, AND GENETIC-ASPECTS, Neurology, 45(4), 1995, pp. 243-244
Authors:
DJALDETTI R
ATLAS D
MELAMED E
Citation: R. Djaldetti et al., SUBCUTANEOUS INJECTIONS OF LEVODOPA ETHYLESTER - A POTENTIAL NOVEL RESCUE THERAPY FOR RESPONSE FLUCTUATIONS IN PATIENTS WITH PARKINSONS-DISEASE, Neurology, 45(4), 1995, pp. 276-276
Authors:
ZIV I
OFFEN D
BARZILAY A
STEIN R
MELAMED E
Citation: I. Ziv et al., THE PROTOONCOGENE BCL-2, A NOVEL CELLULAR PROTECTIVE MECHANISM AGAINST DOPAMINE TOXICITY - POSSIBLE IMPLICATIONS FOR PARKINSONS-DISEASE, Neurology, 45(4), 1995, pp. 279-279